Xcout Intel
WallStreetX ETFs, Inc. competitors & alternatives
The 12 closest competitors and alternatives to WallStreetX ETFs, Inc. among biotechnology companies — ranked by similarity to what WallStreetX ETFs, Inc. actually does, not by market-cap band.
Subscribe to see WallStreetX ETFs, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About WallStreetX ETFs, Inc.
Walking Fish Therapeutics develops cell-based therapeutics by engineering B cells to act as protein factories for the treatment of serious diseases, including oncology, regenerative medicine, autoimmune diseases, and rare deficiency diseases. The company utilizes a proprietary B cell platform to deliver various therapeutic proteins such as replacement proteins, immune-inhibitory proteins, and engineered antibodies.
WallStreetX ETFs, Inc. at a glance
WallStreetX ETFs, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $6M in August 2025. Xcout tracks 3 named people at WallStreetX ETFs, Inc., including JOHNNY WU (ISSUER'S CHIEF EXECUTIVE OFFICER).
WallStreetX ETFs, Inc. leadership
- JOHNNY WUISSUER'S CHIEF EXECUTIVE OFFICER
- Lewis “Rusty” WilliamsCo-founder and CEO
- JOHNNY WUExecutive Officer
WallStreetX ETFs, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $6M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 WallStreetX ETFs, Inc. competitors
Ranked by semantic similarity — how close each company is to WallStreetX ETFs, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Walking Fish Therapeutics, Inc. is a biotechnology company headquartered in South San Francisco, California, focused on engineering B cell-based protein factories to develop novel biotherapeutics for treating serious diseases.
Similar biotechnology company
Blue Marlin Therapeutics is developing a non-viral, in vivo immune-cell engineering platform that combines targeted lipid nanoparticle delivery, genomic integration, and promoter-gated expression. The company aims to provide durable, cell-specific therapies for patients with oncology and autoimmune diseases.
Similar biotechnology company
Be Biopharma is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing engineered B cell therapies.
Biotech
Bellicum Pharmaceuticals, Inc. is a company focused on engineering high-performance cellular immunotherapies. These therapies are developed to combat diseases.
Life Science Tools
BlueWhale Bio, Inc. is dedicated to accelerating the growth and adoption of cell-based therapies by pioneering next-generation cell therapy manufacturing.
Similar biotechnology company
Base Therapeutics is a biotechnology company that develops next-generation gene editing technologies, including its proprietary AccuBase base editing system and enhanced prime editing technology. The company focuses on creating therapeutic solutions for cancer and genetic diseases, alongside engineered immune cell therapies such as BASE-NK and CAR-T products. It serves patients and partners with pharmaceutical and agricultural enterprises by licensing its precision gene editing tools.
Similar biotechnology company
ImCheck Therapeutics designs and develops next-generation immunotherapeutic antibodies focused on modulating the immune system through the butyrophilin and butyrophilin-like superfamily of checkpoint molecules. The company's pipeline targets treatments for cancer, infectious disease, and autoimmune disease.
Biotech
Sail Biomedicines develops a new class of RNA medicines and in vivo CAR-T cell therapies designed to reset autoimmunity and treat immune-mediated diseases. The company utilizes an integrated platform combining Endless RNA (eRNA) constructs and targeted nanoparticles to deliver protein cargos directly to specific immune cells inside the body.
Biotech
AbCellera is a biotechnology company that integrates biology, computation, and engineering to discover and develop antibody-based medicines. The company operates a proprietary technology platform to advance internal and partnered drug programs across therapeutic areas such as endocrinology, immunology, autoimmunity, and oncology.
Similar biotechnology company
Pan Cancer T develops pioneering T-cell receptor (TCR-T) cell therapies designed to empower patients' immune systems to target and overcome solid tumors. The company utilizes proprietary gene engineering to enhance T-cell fitness and persistence against unique cancer-specific intracellular targets.
Biotech
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV). For autoimmune conditions, VTP-1000 is an autoimmune candidate leveraging the proprietary SNAP-TI platform to treat celiac disease. Additionally, VTP-850 is a next-generation immunotherapeutic designed to address recurrent prostate cancer. Furthermore, the preclinical candidate VTP-1100 utilizes the SNAP-CI platform in its development as a potential treatment for HPV-related cancers. Originally established in 2016 under the name Vaccitech plc, the company rebranded to Barinthus Biotherapeutics plc in November 2023. Its main office is located in Harwell, United Kingdom.
Biotech
Elicera Therapeutics is a clinical-stage immuno-oncology company that develops genetically engineered cell and gene therapies, including CAR T-cell therapies and oncolytic viruses, to treat various types of cancer. The company utilizes its proprietary iTANK technology platform to enhance the immune system's ability to target and attack solid tumors.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of WallStreetX ETFs, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for WallStreetX ETFs, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →